TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Recurrent Primary Liver Cancer
Source: Primary Liver Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 17, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent Primary Liver Cancer
Intrahepatic recurrence is the most common pattern of failure after curative treatment.[1] Intrahepatic recurrence of hepatocellular carcinoma (HCC) may be the result of either intrahepatic metastasis or metachronous de novo tumor. Theoretically, intrahepatic metastasis may be associated with less favorable outcomes because it is most likely the result of concurrent hematogenous metastases. However, in clinical practice, the two causes of recurrence cannot be differentiated.
Source links and citations
Treatment options for patients with recurrent primary liver cancer with liver-limited disease without vascular involvement include:
Liver transplant.
Surgical resection.
Ablation.
Radiation therapy.
Evidence (curative radiation therapy):
A randomized controlled trial (NCT04047173) included 166 patients with recurrent HCC (after prior resection or ablation). Patients had a Karnofsky performance status score of at least 90, Child-Pugh class A cirrhosis, and a single HCC (measuring ≤5 cm). Patients were randomly assigned to receive either stereotactic body radiation therapy (SBRT) or radiofrequency ablation (RFA). The primary end point was local progression-free survival (PFS).[2]
Source links and citations
A randomized controlled trial (NCT04047173) included 166 patients with recurrent HCC (after prior resection or ablation). Patients had a Karnofsky performance status score of at least 90, Child-Pugh class A cirrhosis, and a single HCC (measuring ≤5 cm). Patients were randomly assigned to receive either stereotactic body radiation therapy (SBRT) or radiofrequency ablation (RFA). The primary end point was local progression-free survival (PFS).[2]
The local PFS rate was better with SBRT than RFA (hazard ratio [HR], 0.45, 95% confidence interval [CI], 0.24–0.87; P = .04). The 2-year local PFS rates were 92.7% (95% CI, 87.3%–98.5%) with SBRT and 75.8% (95% CI, 67.2%–85.7%) with RFA.[2][Level of evidence B1]
Source links and citations
A randomized controlled trial (NCT04047173) included 166 patients with recurrent HCC (after prior resection or ablation). Patients had a Karnofsky performance status score of at least 90, Child-Pugh class A cirrhosis, and a single HCC (measuring ≤5 cm). Patients were randomly assigned to receive either stereotactic body radiation therapy (SBRT) or radiofrequency ablation (RFA). The primary end point was local progression-free survival (PFS).[2]
There was no statistically significant difference in the 2-year OS rate between the two groups, at 97.6% (95% CI, 94.3%–100.0%) for SBRT and 93.9% (95% CI, 88.9%–99.2%) for RFA (HR, 0.91; 95% CI, 0.37–2.22; P = .830).
A randomized controlled trial (NCT04047173) included 166 patients with recurrent HCC (after prior resection or ablation). Patients had a Karnofsky performance status score of at least 90, Child-Pugh class A cirrhosis, and a single HCC (measuring ≤5 cm). Patients were randomly assigned to receive either stereotactic body radiation therapy (SBRT) or radiofrequency ablation (RFA). The primary end point was local progression-free survival (PFS).[2]
The rate of adverse events was not different between the two groups.
Treatment options for patients with recurrent primary liver cancer with extrahepatic disease or vascular involvement include:
Palliative therapy (transcatheter arterial chemoembolization [TACE] and systemic therapy).
Regarding primary HCC, the treatment strategy for recurrent intrahepatic HCC is determined by the function of the liver and the macroscopic tumor features (e.g., number of lesions, site of recurrence, and invasion of major vessels). Using the same selection criteria that are used for primary HCC, either curative (i.e., salvage liver transplant, surgical resection, and ablation) or palliative treatments (e.g., TACE and sorafenib) can be offered for recurrent HCC.
Evidence (salvage liver transplant, resection, and ablation):
In a retrospective study of 183 patients with intrahepatic recurrence, only 87 of the patients could be treated with curative intent (transplant, resection, and ablation).[3][Level of evidence A2]
Source links and citations
In a retrospective study of 183 patients with intrahepatic recurrence, only 87 of the patients could be treated with curative intent (transplant, resection, and ablation).[3][Level of evidence A2]
The 5-year tumor-free survival rate was 57.9% for liver transplant, 49.3% for resection, and 10.6% for radiofrequency ablation. Subgroup analysis showed that transplant and resection led to comparable survival and that both treatments led to significantly better outcomes than did ablation (P < .001). However, selection bias was a major pitfall of this retrospective study.
In a retrospective study of 183 patients with intrahepatic recurrence, only 87 of the patients could be treated with curative intent (transplant, resection, and ablation).[3][Level of evidence A2]
Other than the use of ablation for secondary treatment, risk factors for shorter disease-free survival were identified as alpha-fetoprotein blood levels above 400 ng/mL and recurrence within 1 year of treatment (47.5% vs. 6.7% at 5 years, P < .001).
Other studies have also suggested that most of the recurrences that appear early during follow-up are caused by tumor dissemination and have a more aggressive biological pattern than primary tumors.[4,5]
Clinical trials are appropriate and can be offered to patients with recurrent HCC whenever possible.
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice